CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 94 enrolled
Drug / intervention
Ociperlimab +2 moredrug
Likely dose
Ociperlimab 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04948697
NCT04948697Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Open-labeled Clinical Study Investigating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab Plus BAT1706 and of Tislelizumab Plus BAT1706 as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

BeiGene·interventional·Posted Jul 2, 2021·Updated Feb 24, 2025

In Brief

A Phase 2 clinical trial evaluating Ociperlimab, Tislelizumab, and 1 other intervention for Advanced Hepatocellular Carcinoma. Completed, enrolled 94 participants across 28 sites in 2 countries.

Detailed Summary

This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in participants with advanced Hepatocellular Carcinoma (HCC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Hepatocellular Carcinoma
CountriesChina, Taiwan
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 2, 2021
Enrollment StartAug 20, 2021
Primary CompletionFeb 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5 years ago

Interventions

Ociperlimabdrug

900 mg intravenously once every 3 weeks (dosed in 21-day cycles)

Tislelizumabdrug

200 mg intravenously once every 3 weeks (dosed in 21-day cycles)

BAT1706drug

15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)